Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

Conclusions
These data are consistent with, and extend, previously published results demonstrating the efficacy of lebrikizumab in improving rate of asthma exacerbations and lung function in patients with moderate-to-severe asthma who remain uncontrolled despite current standard-of-care treatment.

Trial registration numbers
The LUTE study was registered under NCT01545440 and the VERSE study under NCT01545453 at http://www.clinicaltrials.gov

Source: Thorax - July 14, 2015 Category: Respiratory Medicine Authors: Hanania, N. A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S. K., Cheu, M., Putnam, W. S., Murray, E., Scheerens, H., Holweg, C. T., Maciuca, R., Gray, S., Doyle, R., McClintock, D., Olsson, J., Matthews, J. G., Yen, K. Tags: Open access, Asthma, Drugs: respiratory system Respiratory research Source Type: research